Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis

Journal of Clinical Microbiology

Volumn 54, Issue 3, 2016, Pages 727-733

  Farhat, Maha R ^a,b   Jacobson, Karen R ^c,d   Franke, Molly F ^b   Kaur, Devinder ^e   Sloutsky, Alex ^e   Mitnick, Carole D ^b,f   Murray, Megan ^b,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GYR GENE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; MUTATION RATE; PHYLOGENY;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84959500812     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02775-15     Document Type: Article

References (42)

1. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HSF, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. 2013. Aggressive regimens for multidrugresistant tuberculosis decrease all-cause mortality. PLoS One 8:e58664. http://dx.doi.org/10.1371/journal.pone.0058664.
2. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. 2007. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 67:2077-2099. http://dx.doi.org/10.2165/00003495-200767140-00007.
3. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis 51:6-14. http://dx.doi.org/10.1086/653115.
4. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. 2015. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: Implications for treatment. Int J Tuberc Lung Dis 19:339-341. http://dx.doi.org/10.5588/ijtld.14.0814.
5. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
6. Maruri F, Sterling TR, Kaiga AW, Blackman A, Van Der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
7. Hillemann D, Rüsch-Gerdes S, Richter E. 2009. Feasibility of the Geno-Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47:1767-1772. http://dx.doi.org/10.1128/JCM.00081-09.
8. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. 2006. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104-112. http://dx.doi.org/10.1128/AAC.50.1.104-112.2006.
9. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rüsch-Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 53:3353-3356. http://dx.doi.org/10.1128/AAC.00050-09.
10. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005-1015. http://dx.doi.org/10.1056/NEJMoa0907847.
11. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:1683-1689. http://dx.doi.org/10.1128/JCM.01947-09.
12. Small PM, Pai M. 2010. Tuberculosis diagnosis-time for a game change. N Engl J Med 363:1070-1071. http://dx.doi.org/10.1056/NEJMe1008496.
13. Miotto P, Cirillo DM, Migliori GB. 2015. Drug resistance in Mycobacterium tuberculosis: Molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. Chest 147:1135-1143. http://dx.doi.org/10.1378/chest.14-1286.
14. Molina-Moya B, Lacoma A, Prat C, Pimkina E, Diaz J, García-Sierra N, Haba L, Maldonado J, Samper S, Ruiz-Manzano J, Ausina V, Dominguez J. 2015. Diagnostic accuracy study of multiplex PCR for detecting tuberculosis drug resistance. J Infect 71:220-230. http://dx.doi.org/10.1016/j.jinf.2015.03.011.
15. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx.doi.org/10.1371/journal.pone.0039754.
16. Kryazhimskiy S, Rice DP, Jerison ER, Desai MM. 2014. Global epistasis makes adaptation predictable despite sequence-level stochasticity. Science 344:1519-1522. http://dx.doi.org/10.1126/science.1250939.
17. Phillips PC. 2008. Epistasis-the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 9:855-867. http://dx.doi.org/10.1038/nrg2452.
18. Woods RJ, Barrick JE, Cooper TF, Shrestha U, Kauth MR, Lenski RE. 2011. Second-order selection for evolvability in a large Escherichia coli population. Science 331:1433-1436. http://dx.doi.org/10.1126/science .1198914.
19. CLSI document M24-A. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard. CLSI, Wayne, PA.
20. Hardenbol P, Banér J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, Fakhrai-Rad H, Ronaghi M, Willis TD, Landegren U, Davis RW. 2003. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 21:673-678. http://dx.doi.org/10.1038/nbt821.
21. Parish T, Brown AC. 2009. Mycobacteria protocols, 2nd ed. Humana Press, Totowa, NJ.
22. Langmead B. 2010. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics Chapter 11:Unit 11.7. http://dx.doi.org/10.1002/0471250953.bi1107s32.
23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bio informatics/btp352.
24. Lau RWT, Ho P-L, Kao RYT, Yew W-W, Lau TCK, Cheng VCC, Yuen K-Y, Tsui SKW, Chen X, Yam W-C. 2011. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: Functional analysis of gyrA mutation at position 74.Antimicrob Agents Chemother 55:608-614. http://dx.doi.org/10.1128/AAC.00920-10.
25. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniewski FA, Allix-Béguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA, Modernizing Medical Microbiology (MMM) Informatics Group. 2015. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: A retrospective cohort study. Lancet Infect Dis 15:1193-1202. http://dx.doi.org/10.1016/S1473-3099(15)00062-6.
26. Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM. 2014. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 69:2690-2698. http://dx.doi.org/10.1093/jac/dku192.
27. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
28. Kamerbeek J, Schouls L, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, Van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
29. Van Soolingen D, Hermans PW, de Haas PE, Soll DR, Van Embden JD. 1991. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequencedependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 29:2578-2586.
30. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuño L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, de Viedma DG, Garzelli C, Gazzola L, Gomes HM, Guttierez MC, Hawkey PM, Van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ly HM, Martin C, Martin C, Mokrousov I, Narvskaïa O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Rasolonavalona T, Rossetti ML, Rüsch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, Van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006. Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6:23. http://dx.doi.org/10.1186/1471-2180-6-23.
31. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med 6:e2. http://dx.doi.org/10.1371/journal.pmed.1000002.
32. Felsenstein J. 1989. PHYLIP-phylogeny inference package (version 3.2). Cladistics 5:164-166.
33. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. 2014. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun 5:4812. http://dx.doi.org/10.1038/ncomms5812.
34. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 69:1205-1210. http://dx.doi.org/10.1093/jac/dkt535.
35. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. 2015. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: A multicenter study. J Clin Microbiol 53:2961-2969. http://dx.doi.org/10.1128/JCM.01257-15.
36. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 2014. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 69:331-342. http://dx.doi.org/10.1093/jac/dkt358.
37. Sirgel FA, Warren RM, Streicher EM, Victor TC, Van Helden PD, Böttger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. http://dx.doi.org/10.1093/jac/dks033.
38. Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q. 2014. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect 3:e19. http://dx.doi.org/10.1038/emi.2014.21.
39. Chakravorty S, Aladegbami B, Thoms K, Lee JS, Lee EG, Rajan V, Cho E-J, Kim H, Kwak H, Kurepina N, Cho S-N, Kreiswirth B, Via LE, Barry CE, Alland D. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol 49:932-940. http://dx.doi.org/10.1128/JCM.02271-10.
40. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, Zhou L, Xu B, Xu S. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis 16:136-141. http://dx.doi.org/10.1016/S1413-8670(12)70294-5.
41. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52:852-857. http://dx.doi.org/10.1128/AAC .01036-07.
42. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128-1134. http://dx.doi.org/10.1111/j.1469-0691.2011.03551.x.